Arca
Skip to content

Growth hormone deficiency

Drug research and approvals for growth hormone deficiency: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 20 studies of growth hormone deficiency are recruiting on ClinicalTrials.gov, Health Canada has authorized 12 drug trials for it since 2013, FDA has 8 approved and 8 open orphan designations naming it, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 20
  • Trials authorized in Canada: 12
  • FDA orphan approvals: 8
  • EU medicines: 3

Recruiting Now

Newest start dates first, of 20 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 12; search them all in Canada trials
Nov 8, 2022A multicenter, open-label, extension trial to investigate long term efficacy and safety of lonapegsomatropin in adults with growth hormone deficiencyLONAPEGSOMATROPINAscendis PharmaOngoing
Apr 22, 2021Foresight: a multicenter, randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) trial to compare the efficacy and…LONAPEGSOMATROPINAscendis PharmaOngoing
Apr 18, 2019A dose-finding trial evaluating the effect and safety of once-weekly treatment of somapacitan compared to daily norditropin® in children with short stature…SOMAPACITANNovo NordiskClosed
Mar 5, 2019A trial comparing the effect and safety of once weekly dosing of somapacitan with daily norditropin® in children with growth hormone deficiency.NNC0195-0092 (SOMAPACITAN) / NORDITROPIN FLEXPRONovo NordiskOngoing
Jul 24, 2018Enlighten: a multicenter, phase 3, long-term, open-label trial investigating safety and efficacy of transcon hgh administered once-weekly in children with…TRANSCON HGH (ACP-011)Ascendis PharmaPending
Aug 24, 2017A multicenter, phase 3, open-label, 26-week trial investigating the safety, tolerability and efficacy of transcon hgh administered once weekly in children with…TRANSCON HGH (ACP-011)Ascendis PharmaOngoing
Dec 20, 2016A multicenter, phase 3, randomized, open-label, active-controlled, parallel-group trial investigating the safety, tolerability, and efficacy of transcon hgh…TRANSCON HGHAscendis PharmaClosed
Dec 12, 2016A phase 3, open-label, randomized, multicenter, 12 months, efficacy and safety study of weekly mod-4023 compared to daily genotropin therapy in pre-pubertal…MOD-4023 (SOMATROGON)OPKO BIOLOGICS LTD.Ongoing
Oct 4, 2016An open-label, long-term extension study of the safety and efficacy of a long-acting human growth hormone somavaratan (vrs-317) in children with growth hormone…VRS-317 (SOMAVARATAN)VERSARTIS INCClosed
Dec 2, 2015A randomised, multinational, active-controlled, (open-labelled), dose finding, (double-blinded), parallel group trial investigating efficacy and safety of…NNC0195-0092 (SOMAPACITAN) / NORDITROPIN FLEXPRONovo NordiskPending

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 16
Jul 25, 2025Skytrofareplacement of endogenous growth hormone in adults with growth hormone deficiency (GHD)Ascendis Pharma Endocrinology Division A/SApproved
Jun 27, 2023Ngenlatreatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormonePfizer Ireland PharmaceuticalsApproved
Aug 25, 2021SkytrofaTreatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of…Ascendis Pharma Endocrinology Division A/SApproved
Dec 20, 2017MacrelinFor the diagnosis of adult growth hormone deficiencyAeterna Zentaris GmbHApproved
Dec 15, 1997NutropinAs replacement therapy for growth hormone deficiency in adults after epiphyseal closure.Genentech, Inc.Approved
Oct 31, 1997GenotropinTreatment of adults with growth hormone deficiency.Pharmacia & UpjohnApproved
Sep 26, 1997GerefTreatment of idiopathic or organic growth hormone deficiency in children with growth failure.EMD Serono, Inc.Approved
Oct 8, 1996SaizenLong term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.EMD Serono, Inc.Approved
Mar 7, 2022Growth Hormone Releasing Hormone (GHRH) 1-44 Human Amide…Diagnosis of Growth Hormone DeficiencyHollenbeck Pharmaceuticals, Inc.Designated
Dec 19, 2019recombinant human growth hormone fused to…Treatment of Growth Hormone DeficiencyAlteogen, Inc.Designated
Jun 15, 2017ibutamoren mesylateTreatment of growth hormone deficiencyLumos Pharma LLCDesignated
Nov 9, 2016recombinant growth hormone fused to hyFcTreatment of growth hormone deficiency.Genexine, Inc.Designated
Feb 23, 2016growth hormone releasing hormone, 1-44 human amideTreatment of growth hormone deficiencyHollenbeck Pharmaceuticals, Inc.Designated
Oct 16, 2013somavaratanTreatment of growth hormone deficiencyVersartis, Inc.Designated
Oct 18, 2012pralmorelin hydrochlorideAs a diagnostic agent for the detection of growth hormone deficiencySella Pharmaceuticals, Inc.Designated

Medicines Authorised in the EU

Newest first

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.